Zealand Pharma A/S
Zealand Pharma A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach to peptide-based therapeutics. Founded in 1998, the company has made significant strides in the biopharmaceutical industry, focusing on the development of novel treatments for diabetes, obesity, and gastrointestinal disorders. With a strong presence in Europe and North America, Zealand Pharma is committed to advancing its core products, which include unique peptide therapies that offer targeted solutions for complex health issues. The company has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its position as a key player in the global biopharmaceutical market. Zealand Pharma's dedication to scientific excellence and patient-centric solutions continues to drive its growth and impact in the healthcare landscape.
DitchCarbon Score
How does Zealand Pharma A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zealand Pharma A/S's score of 42 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Zealand Pharma A/S's reported carbon emissions
In 2024, Zealand Pharma A/S reported total carbon emissions of approximately 266,557,000 kg CO2e. This figure includes 145,000 kg CO2e from Scope 1 emissions, 17,000 kg CO2e from Scope 2 emissions (location-based), and a significant 266,412,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (42,712,000 kg CO2e), business travel (577,000 kg CO2e), and employee commuting (254,000 kg CO2e). In 2023, the company recorded total emissions of about 73,923,000 kg CO2e, with Scope 1 emissions at 144,000 kg CO2e, Scope 2 emissions at 56,000 kg CO2e (location-based), and Scope 3 emissions reaching 73,757,000 kg CO2e. This indicates a substantial increase in emissions from 2023 to 2024. Zealand Pharma has committed to achieving net-zero emissions, as indicated by their near-term target status of "Committed" under the Science Based Targets initiative (SBTi). However, specific reduction targets or timelines have not been disclosed. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is headquartered in Denmark. Overall, Zealand Pharma A/S is actively engaging in climate commitments, although detailed reduction initiatives and specific targets remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 144,000 | 000,000 |
| Scope 2 | 23,000 | - |
| Scope 3 | 73,757,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zealand Pharma A/S is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
